TITLE:
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

CONDITION:
Chronic Hepatitis C

INTERVENTION:
Viramidine

SUMMARY:

      The purpose of this study is to determine the safety and effectiveness of viramidine to
      ribavirin in chronic hepatitis C patients who have never before received treatment.
    

DETAILED DESCRIPTION:

      Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin
      1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a
      to treatment-naive patients with chronic hepatitis C (CHC)
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Treatment-naive patients with compensated chronic hepatitis C.

          -  HCV RNA >2000 copies/mL (780 IU/mL) as determined by NGI SuperQuant serum HCV RNA
             quantification, with a lower limit of detection of 100 copies/mL (39 IU/mL).

        Exclusion Criteria:

          -  Severe neuropsychiatric disorders

          -  History or clinical manifestations of significant metabolic, hematological,
             pulmonary, ischemic heart disease, significant or unstable heart disease,
             gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic
             disorders including severe retinopathy, or immune mediated disease

          -  Pregnant or breast-feeding patients
      
